Roivant Sciences (ROIV) director awarded 405 fully vested shares

Rhea-AI Filing Summary

MOMTAZEE JAMES C reported acquisition or exercise transactions in this Form 4 filing.

Roivant Sciences Ltd. director James C. Momtazee received an award of 405 Common Shares on July 17, 2026 under the Non-Employee Director Compensation Plan at $0.00 per share. The award was fully vested on grant, bringing his directly held stake to 109,810 Common Shares.

Insider Trade Summary

Net Buyer: 405 shares

Net Buy 1 txn

Insider MOMTAZEE JAMES C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	405	$0.00	$0.00

Holdings After Transaction: Common Shares — 109,810 shares (Direct)

Footnotes (1)

1. F1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Key Figures

Shares granted: 405 Common Shares Grant price: $0.00 per share Holdings after transaction: 109,810 Common Shares +1 more

4 metrics

Shares granted 405 Common Shares Award of Common Shares on July 17, 2026 under Non-Employee Director Compensation Plan

Grant price $0.00 per share Reported transaction price per share for the 405-share award

Holdings after transaction 109,810 Common Shares Directly held Roivant Sciences Common Shares following the award

Transaction date July 17, 2026 Date of grant/award acquisition reported on Form 4

Key Terms

Non-Employee Director Compensation Plan, Common Shares, Power of Attorney

3 terms

Non-Employee Director Compensation Plan financial

"received pursuant to the Issuer's Non-Employee Director Compensation Plan"

Common Shares financial

"Reflects an award of Common Shares received pursuant to the Issuer's plan"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Power of Attorney regulatory

"Remarks note: Exhibit 24 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/21/2026 - 09:00 PM Accepted by SEC EDGAR 07/21/2026 - 09:00 PM Learn about SEC filing dates

FAQ

What insider transaction did James C. Momtazee report for Roivant Sciences (ROIV)?

James C. Momtazee reported receiving an award of 405 Roivant Sciences Common Shares as director compensation. The shares were granted on July 17, 2026, at $0.00 per share and were fully vested immediately under the Non-Employee Director Compensation Plan.

How did the July 17, 2026 share award affect Momtazee’s ROIV holdings?

After the grant of 405 Common Shares, James C. Momtazee’s directly held position increased to 109,810 Common Shares. This Form 4 shows only an acquisition; there were no reported sales or derivative exercises in this filing.

Was James C. Momtazee’s ROIV share grant made under a compensation plan?

Yes. The 405-share award was received under Roivant Sciences’ Non-Employee Director Compensation Plan. A footnote explains that the Common Shares granted pursuant to this plan were fully vested as of the grant date, meaning no further vesting conditions applied.

Did James C. Momtazee pay anything for the 405 Roivant Sciences shares?

No. The reported transaction price is $0.00 per share, indicating the 405 Common Shares were granted as compensation rather than purchased in the market. The Form 4 classifies the event as a grant, award, or other acquisition of non-derivative securities.

Was Momtazee’s Roivant Sciences (ROIV) share award under a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is not checked, and the filing does not describe the grant as pursuant to a trading plan. It characterizes the transaction simply as a director compensation award under the Non-Employee Director Compensation Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOMTAZEE JAMES C

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/17/2026		A		405(1)	A	$0(1)	109,810	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Remarks:

Exhibit 24 - Power of Attorney

	By: /s/ Sam Kaplan, as Attorney-in-Fact for James C Momtazee	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)